Khan K M Faisal, Howe Louise R, Falcone Domenick J
Department of Pathology and Laboratory Medicine, Joan and Sanford I. Weill Medical College, Cornell University, New York, New York 10021, USA.
J Biol Chem. 2004 May 21;279(21):22039-46. doi: 10.1074/jbc.M312735200. Epub 2004 Mar 15.
Chronic inflammatory diseases are characterized by the persistent presence of macrophages and other mononuclear cells, tissue destruction, cell proliferation, and the deposition of extracellular matrix (ECM). The tissue degradation is mediated, in part, by enhanced proteinase expression by macrophages. It has been demonstrated recently that macrophage proteinase expression can be stimulated or inhibited by purified ECM components. However, in an intact ECM the biologically active domains of matrix components may be masked either by tertiary conformation or by complex association with other matrix molecules. In an effort to determine whether a complex ECM produced by vascular smooth muscle cells (SMC) regulates macrophage degradative phenotype, we prepared insoluble SMC matrices and examined their ability to regulate proteinase expression by RAW264.7 and thioglycollate-elicited peritoneal macrophages. Here we demonstrate that macrophage engagement of SMC-ECM triggers PKC-dependent activation of MAPK(erk1/2) leading to increased expression of cyclooxygenase (COX)-2 and prostaglandin (PG) E(2) synthesis. The addition of PGE(2) to macrophage cultures stimulates their expression of both urokinase-type plasminogen activator and MMP-9, and the selective COX-2 inhibitor NS-398 blocks ECM-induced proteinase expression. Moreover, ECM-induced PGE(2) and MMP-9 expression by elicited COX-2(-/-) macrophages is markedly reduced when compared with the response of either COX-2(+/-) or COX-2(+/+) macrophages. These data clearly demonstrate that SMC-ECM exerts a regulatory role on the degradative phenotype of macrophages via enhanced urokinase-type plasminogen activator and MMP-9 expression, and identify COX-2 as a targetable component of the signaling pathway leading to increased proteinase expression.
慢性炎症性疾病的特征是巨噬细胞和其他单核细胞持续存在、组织破坏、细胞增殖以及细胞外基质(ECM)沉积。组织降解部分是由巨噬细胞增强的蛋白酶表达介导的。最近已证明,纯化的ECM成分可刺激或抑制巨噬细胞蛋白酶表达。然而,在完整的ECM中,基质成分的生物活性结构域可能会被三级构象或与其他基质分子的复杂结合所掩盖。为了确定血管平滑肌细胞(SMC)产生的复杂ECM是否调节巨噬细胞的降解表型,我们制备了不溶性SMC基质,并检查了它们调节RAW264.7和巯基乙酸诱导的腹腔巨噬细胞蛋白酶表达的能力。在此我们证明,巨噬细胞与SMC-ECM的相互作用触发了PKC依赖的MAPK(erk1/2)激活,导致环氧化酶(COX)-2表达增加和前列腺素(PG)E(2)合成增加。向巨噬细胞培养物中添加PGE(2)可刺激其尿激酶型纤溶酶原激活剂和MMP-9的表达,而选择性COX-2抑制剂NS-398可阻断ECM诱导的蛋白酶表达。此外,与COX-2(+/-)或COX-2(+/+)巨噬细胞的反应相比,COX-2(-/-)巨噬细胞诱导的ECM诱导的PGE(2)和MMP-9表达明显降低。这些数据清楚地表明,SMC-ECM通过增强尿激酶型纤溶酶原激活剂和MMP-9的表达对巨噬细胞的降解表型发挥调节作用,并将COX-2确定为导致蛋白酶表达增加的信号通路中可靶向的成分。